C.B. Eap

Discipline

Psychologie (15) Sociologie (6) Education (2) Linguistique (1)

Type de document

Articles (72) Recensions (9) Autres (1) Livres et chapitres d'ouvrages (1)

Co-auteur

Date

Source

Mot-clé

Patients (43) Human beings (42) Patients (41) Treatment (37) risque (27) adulte (27) Risk (27) adulte (27) cohorte (24) âge (23) Age (23) Age (23) association (22) Social groups (22) Psychotropic drugs (21) Older people (20) effet (19) poids (18) dose (18) Weight gain (18) Population (18) Weight (18) Population (18) Analysis (17) analyse (16) Obesity (16) Months (16) Body mass index (16) Influence (16) Drugs (15)

Documents écrit par C.B. Eap (73) | parle de C.B. Eap (0)

Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis.
N. Kuzo et al.
Prescription d’antipsychotiques chez les adultes : à quoi faut-il être attentif ? [Antipsychotic prescribing in adults : what to watch out for ?]
C. Grandjean et al. (20 sept. 2023)
Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study.
M. Piras et al. (4 juil. 2023)
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
J. Sjaarda et al.
Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study.
M. Piras et al. (3 janv. 2023)
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.
B.I. Perry et al.
CYP2C19 expression modulates affective functioning and hippocampal subiculum volume-a large single-center community-dwelling cohort study.
C. Grosu et al. (5 août 2022)
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
N. Laaboub et al. (17 mai 2022)
Daily Dose Effects of Risperidone on Weight and Other Metabolic Parameters: A Prospective Cohort Study.
M. Piras et al. (9 mai 2022)
Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.
G. Schoretsanitis et al.
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.
A.F. Pardiñas et al. (1 mars 2022)
Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.
M. Smogur et al.
Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity.
V. Guinchat et al. (2022)
Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema.
G. Buso et al. (2022)
Gabapentinoïdes : mésusages et addictions [Gabapentinoids : misuses and addictions]
C. Grandjean et al. (15 déc. 2021)
Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study.
C. Dubath et al.
Recommandations de prise en charge des mésusages et addictions aux benzodiazepines [Recommendations for management of misuses and addictions to benzodiazepines]
C. Grandjean et al. (13 oct. 2021)
French validation of the M-Back questionnaire: assessing clinicians' knowledge about metabolic syndrome in psychiatry
P. Golay et al. (10 oct. 2021)
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
C. Dubath et al. (7 oct. 2021)
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
C.B. Eap et al.
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population.
A. Delacrétaz et al.
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
C. Dubath et al. (26 juin 2021)
Traitement de l’insomnie, par quoi commencer ? [Treatment of insomnia, with what to start ?]
C. Grandjean et al. (5 mai 2021)
Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass.
F. Vandenberghe et al.
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.
N. Laaboub et al. (2021)

next